Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
451.73
-9.51 (-2.06%)
At close: Sep 17, 2025, 4:00 PM EDT
453.20
+1.47 (0.33%)
After-hours: Sep 17, 2025, 5:45 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,104,019
Profits / Employee
-$143,089
Market Cap
59.21B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,230 | 130 | 6.19% |
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | 1,323 | 258 | 24.23% |
Dec 31, 2018 | 1,065 | 316 | 42.19% |
Dec 31, 2017 | 749 | 235 | 45.72% |
Dec 31, 2016 | 514 | 145 | 39.30% |
Dec 31, 2015 | 369 | 113 | 44.14% |
Dec 31, 2014 | 256 | 91 | 55.15% |
Dec 31, 2013 | 165 | 36 | 27.91% |
Dec 31, 2012 | 129 | 13 | 11.21% |
Dec 31, 2011 | 116 | -56 | -32.56% |
Dec 31, 2010 | 172 | -6 | -3.37% |
Dec 31, 2009 | 178 | 8 | 4.71% |
Dec 31, 2008 | 170 | 41 | 31.78% |
Dec 31, 2007 | 129 | 7 | 5.74% |
Dec 31, 2006 | 122 | 28 | 29.79% |
Dec 31, 2005 | 94 | 23 | 32.39% |
Dec 31, 2004 | 71 | 11 | 18.33% |
Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALNY News
- 7 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes - Business Wire
- 9 days ago - Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes - Business Wire
- 14 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript - Seeking Alpha
- 14 days ago - Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives - Seeking Alpha
- 17 days ago - New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM - Business Wire
- 18 days ago - Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension - Business Wire
- 18 days ago - Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial - Business Wire